Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation

American Journal of Transplantation

Volumn 8, Issue 10, 2008, Pages 2126-2131

  Muthusamy, A S R ^a   Vaidya, A C ^a   Sinha, S ^a   Roy, D ^a   Elker, D E ^a   Friend, P J ^a,b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Alemtuzumab; Immunosuppression; Pancreas transplantation; Steroid avoidance

Indexed keywords

ALEMTUZUMAB; COTRIMOXAZOLE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; STEROID; TACROLIMUS; VALACICLOVIR; VALGANCICLOVIR;

ADULT; ARTICLE; BLEEDING; CYTOMEGALOVIRUS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY PANCREAS TRANSPLANTATION; LUNG EDEMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RASH; REOPERATION; THROMBOCYTOPENIA;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; CHILD; CHILD, PRESCHOOL; FEMALE; GLYCOPROTEINS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTES; MALE; MYCOPHENOLIC ACID; PANCREAS TRANSPLANTATION; RETROSPECTIVE STUDIES; STEROIDS; TACROLIMUS;

EID: 51849154732     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02373.x     Document Type: Article

References (32)

1. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006 19 : 705 714.
2. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003 76 : 120 129.
3. Trzonkowski P, Zilvetti M, Friend P, Wood KJ. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation 2006 82 : 1342 1351.
4. Isaacs JD, Manna VK, Rapson N et al. CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study. Br J Rheumatol 1996 35 : 231 240.
5. Jones JL, Coles AJ. Campath-1H treatment of multiple sclerosis. Neurodegener Dis 2008 5 : 27 31.
6. Jacobsohn DA. Emerging therapies for graft-versus-host disease. Expert Opin Emerg Drugs 2003 8 : 323 338.
7. Friend PJ, Waldmann H, Hale G et al. Reversal of allograft rejection using the monoclonal antibody, Campath-1G. Transplant Proc 1991 23 : 2253 2254.
8. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998 351 : 1701 1702.
9. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): A systematic review in organ transplantation. Transplantation 2006 81 : 1361 1367.
10. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction-long-term results. Am J Transplant 2005 5 : 2539 2548.
11. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am J Transplant 2006 6 : 331 339.
12. Gruessner RW, Kandaswamy R, Humar A, Gruessner AC, Sutherland DE. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 2005 79 : 1184 1189.
13. Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005 5 : 3009 3014.
14. Gallon LG, Winoto J, Leventhal JR, Parker MA, Kaufman DB. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol 2006 1 : 1029 1038.
15. Friend PJ, Hale G, Waldmann H et al. Campath-1M-prophylactic use after kidney transplantation. A randomized controlled clinical trial. Transplantation 1989 48 : 248 253.
16. Hale G, Waldmann H, Friend P, Calne R. Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation. Transplantation 1986 42 : 308 311.
17. Thamboo TP, Jeffery KJ, Friend PJ, Turner GD, Roberts IS. Urine cytology screening for polyoma virus infection following renal transplantation: The Oxford experience. J Clin Pathol 2007 60 : 927 930.
18. Vaidya AMA, Hadjianastassiou VG, Roy D et al. Simultaneous pancreas-kidney transplantation: To anticoagulate or not? Is that a question? Clinical Transplantation 2007 21 : 554 557.
19. Krebs TL, Daly B, Wong-You-Cheong JJ, Carroll K, Bartlett ST. Acute pancreatic transplant rejection: Evaluation with dynamic contrast-enhanced MR imaging compared with histopathologic analysis. Radiology 1999 210 : 437 442.
20. Hurst GC, Somerville KT, Alloway RR, Gaber AO, Stratta RJ. Preliminary experience with midodrine in kidney/pancreas transplant patients with orthostatic hypotension. Clin Transplant 2000 14 : 42 47.
21. Axelrod D, Leventhal JR, Gallon LG, Parker MA, Kaufman DB. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. Am J Transplant 2005 5 : 1423 1429.
22. Thai NL, Abu-Elmagd K, Khan A et al. Pancreatic transplantation at the University of Pittsburgh. Clin Transpl 2004 : 205 214.
23. Sundberg AK, Roskopf JA, Hartmann EL, Farney AC, Rohr MS, Stratta RJ. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation. Transplant Proc 2005 37 : 1294 1296.
24. Kuhr CS, Davis CL, Barr D et al. Use of ultrasound and cystoscopically guided pancreatic allograft biopsies and transabdominal renal allograft biopsies: Safety and efficacy in kidney-pancreas transplant recipients. J Urol 1995 153 : 316 321.
25. Aideyan OA, Schmidt AJ, Trenkner SW, Hakim NS, Gruessner RW, Walsh JW. CT-guided percutaneous biopsy of pancreas transplants. Radiology 1996 201 : 825 828.
26. Atwell TD, Gorman B, Larson TS, Charboneau JW, Ingalls Hanson BM, Stegall MD. Pancreas transplants: Experience with 232 percutaneous US-guided biopsy procedures in 88 patients. Radiology 2004 231 : 845 849.
27. Marroquin CE, Edwards EB, Collins BH, Desai DM, Tuttle-Newhall JE, Kuo PC. Half-life analysis of pancreas and kidney transplants. Transplantation 2005 80 : 272 275.
28. Clatworthy MR, Sivaprakasam R, Butler AJ, Watson CJ. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation. Transplantation 2007 84 : 1563 1567.
29. Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc 2005 37 : 934 936.
30. Thai NL, Khan A, Tom K et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation 2006 82 : 1621 1624.
31. Watson CJ, Bradley JA, Friend PJ et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005 5 : 1347 1353.
32. Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 2004 9 : 409 411.